Navigation Links
MIT: Jeremy Nathans to deliver Scolnick Prize lecture
Date:4/23/2009

April 23, 2009, Cambridge, MA --- The McGovern Institute for Brain Research at MIT will present the sixth annual Edward M. Scolnick Prize in Neuroscience to Jeremy Nathans, a Howard Hughes Medical Institute Investigator and professor of molecular biology and genetics, neuroscience, and opthalmology at Johns Hopkins University School of Medicine.

Dr. Nathans will deliver the Scolnick Prize lecture entitled "The Evolution of Trichromatic Color Vision" at the McGovern Institute on Monday, April 27, 2009 at 4 pm in the MIT Cognitive Sciences Complex, 43 Vassar Street (building 46, room 3002). The lecture, followed by a reception, is free and open to the public.

The Scolnick Prize is awarded annually by the McGovern Institute to recognize an individual who has made outstanding advances in the field of neuroscience. Nathans will receive the prize for his contributions to the understanding of color vision, brain development, and retinal disease.

"Jeremy Nathans exemplifies the spirit of discovery that we honor through this award," says Robert Desimone, director of the McGovern Institute and chair of the selection committee. "His pioneering work on the mechanism of color vision has led to an extraordinary range of insights into the function and development of the brain, as well as the basis for many forms of human blindness."

In work that he began when he was a graduate student, Nathans solved the mystery of the origin of human color blindness. Using his own DNA, he identified the genes for the three color-sensitive pigment proteins in the human retina. He showed that mutations in these genes cause can lead to different forms of color blindness, and that the red and green pigment genes are on the X-chromosome, which is why red-green color blindness is more common in men than women.

In addition to explaining the molecular basis of color vision, the discovery of these pigment proteins and the related protein rhodopsin was important because they are prototypes of a large family of proteins known as G-protein-coupled receptors. These proteins are key signaling molecules in all known organisms, and they represent the targets for about 1/3 of all FDA-approved drugs.

In more recent studies, Nathans and his colleagues discovered how genes control the normal development of the retina, and how defects in these genes disrupt the function and survival of retinal cells. These studies have revealed several defects that lead to human retinal diseases including Stargardt disease, the most common type of macular degeneration in children and young adults.

Nathans and colleagues also determined that the vitelliform type of macular dystrophy is caused by abnormalities in a member of a previously unknown family of ion channels proteins that allow ions to enter and exit cells.


'/>"/>

Contact: Julie Pryor
jpryor@mit.edu
617-715-5397
McGovern Institute for Brain Research
Source:Eurekalert  

Related biology news :

1. Jeremy Jackson honored by Harvard Museum of Natural History
2. New type of vaccines deliver stronger and faster immune response
3. Depression during pregnancy can double risk of preterm delivery
4. Self-assembling nano-fiber gel delivers high concentrations of clinically approved drugs
5. RNA molecules, delivery system improve vaccine responses, effectiveness
6. Sig-Tec(R) and BIO-key(R) Deliver Advanced Biometric Security Solution to Ohio County Law Enforcement Agency
7. Jefferson scientists deliver toxic genes to effectively kill pancreatic cancer cells
8. ID Solutions Achieves Full-Production Delivery and Payment for Fingerprint Processing Software for TWIC
9. Promptu and OAG Team to Deliver Flight Schedule and Status Information on Mobile Devices
10. Energy secretary, IEEE-member industry leader to deliver keynote addresses during GridWeek 2008
11. Slipping through cell walls, nanotubes deliver high-potency punch to cancer tumors in mice
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
MIT: Jeremy Nathans to deliver Scolnick Prize lecture
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
(Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology: